MapLight Therapeutics, Inc.

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system (CNS) disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform aims to identify neural circuits causally linked to disease and target those circuits for therapeutic modulation. Our lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC). We are initially developing ML-007C-MA for the treatment of schizophrenia and Alzheimer's disease psychosis (ADP). This candidate is designed to activate both M1 and M4 muscarinic receptors centrally to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. ML-007, either alone, co-administered, or co-formulated with PAC, has been evaluated in four Phase 1 trials, involving a total of 270 healthy participants and more than 1,500 doses of ML-007 administered. We are currently conducting ZEPHYR, a Phase 2 trial evaluating ML-007C-MA for the treatment of schizophrenia. We expect this trial to reach its target enrollment of 300 participants in April 2026 and report topline results in the third quarter of 2026. Additionally, we are conducting VISTA, a Phase 2 trial evaluating ML-007C-MA for the treatment of ADP, and expect to report topline results in the second half of 2027.